Will Imaging Assist in the Selection of Patients With Heart Failure for an ICD?  by Gerson, Myron C. et al.
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yron C. Gerson, MD,*† Mouhamad Abdallah, MD,* James N. Muth, MD, PHD,*
lexandru I. Costea, MD*
incinnati, Ohio
udden cardiac death remains the leading cause of death in the U.S. A left ventricular ejection fraction
LVEF) 30% to 35% identifies a population of patients at increased risk for sudden cardiac death.
nce identified, an implantable cardioverter-defibrillator (ICD) is effective in reducing the occurrence
f sudden cardiac death. Yet in a substantial proportion of patients who receive an ICD based on
educed LVEF, the device never delivers therapy. Furthermore, the majority of patients who die
uddenly do not qualify for ICD placement under current LVEF-based criteria in the guidelines. This
eview considers the potential role of cardiac imaging in improving the selection of patients most
ikely to benefit from an ICD. The presence of myocardial scar and/or unrevascularized myocardial
schemia provides an important substrate for the occurrence of potentially fatal ventricular arrhyth-
ias. The presence of clinical heart failure further increases the risk of ventricular arrhythmia. The
ympathetic nervous system provides an important trigger formajor arrhythmic events, both through
lobal overactivity and through regional heterogeneity of sympathetic activity. A mismatch of myo-
ardial perfusion and innervation may pose a particularly great risk. Imaging modalities provide
nique opportunities to investigate the anatomic and pathophysiologic substrates, as well as the
riggering effects of cardiac sympathetic innervation. Combining imaging and electrophysiologic
odalities offers promise for improved accuracy in future selection of patients with heart failure for
CD placement. (J AmColl Cardiol Img 2010;3:101–10) © 2010 by the American College of Cardiology
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gingudden cardiac death (SCD) remains the leading
ause of death in the U.S. Unfortunately, success
n prospectively identifying individual patients at
isk before the occurrence of SCD has been
imited. Patients with left ventricular ejection
raction (LVEF) 30% to 35% are at increased
isk for SCD, and an implantable cardioverter-
efibrillator (ICD) in these patients has been
ocumented to reduce mortality resulting from
entricular arrhythmias (1). Although very help-
ul, reduced LVEF is a nonspecific predictor of
otentially fatal arrhythmic events. In a substan-
rom the *Division of Cardiovascular Diseases, University of Cinci
E. L. Saenger Radioisotope Laboratory, University Hospital of C
ohn R. Strauss Fund for Research and Education in Cardiac Imaanuscript received April 6, 2009; revised manuscript received July 24ial proportion of patients who receive an ICD
ased on reduced LVEF, the device never deliv-
rs therapy over its lifetime. Furthermore, many
atients with LVEF 30% die from progressive
eart failure and not SCD. Current American
ollege of Cardiology/American Heart Associa-
ion guidelines recommend ICD placement for
rimary prevention of fatal ventricular arrhyth-
ias in patients with New York Heart Associa-
ion (NYHA) functional class II or III symp-
oms, while they are undergoing optimal
edical treatment, and who have reasonable
i College of Medicine, Cincinnati, Ohio; and the
nati, Cincinnati, Ohio. Supported in part by the
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102xpectation of survival with good functional sta-
us for more than 1 year (2). Only approximately
ne-third of patients who die suddenly have
VEF that meets LVEF-based criteria for pro-
hylactic ICD placement under the current
uidelines (3).
A recent scientific statement from the American
ollege of Cardiology/American Heart Associa-
ion/Heart Rhythm Society reviews numerous elec-
rocardiographic and autonomic reflex-based tests
hat have been used to identify patients at risk for
CD (4). The statement concludes that the “opti-
al way to combine and use the techniques in
linical practice remains unclear.” With the excep-
ion of measurement of LVEF, the scientific state-
ent provides minimal information on the use of
imaging techniques for identification of
patients at risk for SCD. The present
review considers imaging approaches to
guide the selection of patients for ICD
placement, with specific focus on the ar-
rhythmogenic role of the sympathetic ner-
vous system in a context of myocardial scar
and/or ischemia.
Myocardial Scar
The extent of myocardial scar is predictive
of inducibility of ventricular arrhythmias
at electrophysiologic study (5), and it has
been reported to be more predictive of
total mortality (6,7) and SCD than is
LVEF. Morishima et al. (8) reported that
single-photon emission computed tomog-
raphy (SPECT) myocardial perfusion de-
fect size at rest was the strongest predictor
of lethal arrhythmic events over 30
months of follow-up among 106 patients
ith MADIT II (Multicenter Automatic Defibril-
ator Implantation Trial II) criteria for ICD place-
ent. Cardiac magnetic resonance (CMR) with
ate gadolinium enhancement has been used to dem-
nstrate myocardial scar in patients with nonischemic
nd ischemic cardiomyopathy. In some patients with
onischemic cardiomyopathy, SCD is believed to
esult from the presence of myocardial scar (9,10),
hich provides a substrate for reentrant ventricular
rrhythmias (Figs. 1 and 2). Wu et al. (11) performed
prospective study of 65 patients with nonischemic
ardiomyopathy prior to ICD placement with a me-
ian follow-up of 17 months for end points of SCD or
ppropriate ICD discharge. End points were detected
ion
ssionn 22% of patients with CMR evidence of myocardial icar versus only 8% of patients without evidence of
adolinium enhancement (p  0.03).
yocardial Ischemia
schemia, including myocardial ischemia at rest
hibernation), is recognized as a trigger for ventric-
lar arrhythmias (12,13). Revascularization that
lleviates ischemia reduces the rate of inducibility of
entricular arrhythmias at electrophysiologic study
14) and reduces the incidence of SCD (15). van der
urg et al. (16) reported that survivors of SCD who
ere found to have jeopardized myocardium on
ipyridamole perfusion imaging, and who then
nderwent revascularization, had a relatively low
ate of death or recurrent ventricular arrhythmia
14% over 3 years). In comparison, patients not
evascularized had a 38% rate of death or recurrent
entricular arrhythmia over 3 years (p  0.05).
lhendy et al. (17) followed 90 patients with
oronary disease who received an ICD for primary
r secondary prevention of SCD. In this study, 72%
f patients had undergone prior coronary artery
ypass surgery. Ischemia manifest as new or wors-
ning wall motion abnormality on stress echocardi-
graphy was an independent predictor of death and
CD therapy during 2.8  1.5 years of follow-up
Fig. 3). In the Coronary Artery Bypass Graft Patch
tudy, 900 patients with LVEF 36% and abnor-
al signal-averaged electrocardiogram were ran-
omized to receive or not receive an ICD at the
ime of coronary artery bypass graft surgery. There
as no difference in the incidence of sustained
entricular tachycardia or ventricular fibrillation
etween the groups. The authors speculated that
omplete surgical revascularization with relief of
schemic substrate may have explained the lack of
enefit of ICD implantation in these apparently
igh-risk patients (18).
ombinedMyocardial Ischemia and Scar
here is evidence that the total extent of myocardial
car plus ischemia may provide stronger prediction
f major ventricular arrhythmias (19) and SCD
ompared with either measurement alone. Piccini et
l. (20) analyzed a cohort of 6,383 patients with
ngiographically documented coronary artery dis-
ase who underwent SPECT myocardial perfusion
maging. Sudden cardiac death occurred in 215
atients (3.4%) over 6.1 years of follow-up. After
djustments for LVEF and clinical variables, the
ummed stress score, representing fixed plus revers-B B R E V I A T I O N S
N D A C R O N YM S
NP B-type natriuretic
eptide
MR cardiac magnetic
esonance
/M heart to mediastinum
CD implantable
ardioverter-defibrillator
VEF left ventricular eject
raction
IBG
eta-iodobenzylguanidine
YHA New York Heart
ssociation
ET positron emission
omography
CD sudden cardiac death
PECT single-photon emible defects on SPECT myocardial perfusion im-
a
o
t
a
o
t
s
Y
d
l
a
w
s
r
w
2
r
p
p
c
(
a
v
s
i
d
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 , 2 0 1 0
J A N U A R Y 2 0 1 0 : 1 0 1 – 1 0
Gerson et al.
Imaging in Selection of Patients With HF for ICD
103ges, remained significantly associated with the
ccurrence of SCD. Among perfusion indices, only
he summed stress score was predictive of SCD on
djusted analysis, suggesting that the combination
f scar and ischemia has greater predictive power
han either scar or ischemia alone (Fig. 4). Further
upport for this concept arose from a CMR study by
an et al. (21) of 144 patients with coronary artery
isease and myocardial delayed enhancement fol-
owing gadolinium-diethylenetriamine penta-acetic
cid administration. Core myocardial infarct zones
ere identified by having gadolinium signal inten-
ity more than 3 standard deviations above that of
BA
Figure 1. Pathologic and Cardiac Magnetic Resonance Demonst
Nonischemic Cardiomyopathy
(A) Pathologic short-axis section through the left and right ventricle
in the inferior, lateral, and septal walls from a patient with nonische
presence of collagen in a microscopic section from the area of ﬁbro
nance image of the same myocardial slice illustrating the correlatio
Reproduced with permission from Assomull et al. (10).
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Figure 2. Prediction of Sudden Cardiac Death by LGE
(A) Kaplan-Meier estimates for the combined end point of sudden c
(LGE) or absence (LGE) of LGE. (B) The same data adjusted for b
with permission from Assomull et al. (10). LGE  late gadolinium enhanemote normal myocardium. Peri-infarction zones
ere identified as having signal-intensity thresholds
to 3 standard deviations greater than remote normal
egions. After adjustments for age and LVEF, the
ercentage of the total infarct area localized to the
eri-infarct zone was independently associated with
ardiovascular mortality with a hazard ratio of 1.49
p  0.01). These CMR methods have also been
pplied to the prediction of sustained monomorphic
entricular tachycardia during electrophysiologic
tudy or device interrogation (19). For 20 patients
nducible with monomorphic ventricular tachycar-
ia and 27 patients who were not inducible, there
C
n of Myocardial Fibrosis in
mid-ventricular level showing mid-wall ﬁbrosis (straight arrows)
dilated cardiomyopathy. (B) Sirius red staining conﬁrming the
in the pathologic section. (C) Premortem cardiac magnetic reso-
areas of late gadolinium enhancement with pathologic ﬁbrosis.
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104ere no baseline differences in CMR measurements
f LVEF, LV volumes, and infarct size. By multi-
ariate analysis, the extent of the peri-infarction
yperenhancement zone was the only significant
redictor of inducibility for monomorphic ventric-
lar tachycardia. These studies suggest an impor-
Ischemia
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Figure 3. Prediction of Sudden Cardiac Death or Implantable Ca
Kaplan-Meier curves indicating freedom from sudden cardiac death
with coronary artery disease at high risk for arrhythmic death. Risk
detected by stress echocardiography. Independent predictors of ev
tained ventricular tachycardia (hazard ratio [HR]: 1.9; 95% conﬁdenc
on electrophysiologic study (HR: 1.7; 95% CI: 1.2 to 4.5; p  0.01), a
duced with permission from Elhendy et al. (17).
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Figure 4. Prediction of SCD From Combined Myocardial
Ischemia and Scar
Relative contribution of the extent of myocardial ischemia plus
scar to estimating sudden cardiac death (SCD) when compared
with clinical risk factors and left ventricular ejection fraction
(LVEF). When compared with the clinical index, LVEF contributes
48.3% of the prognostic model content for estimating SCD. By
comparison, the combination of EF  summed stress score (SSS)
contributes 51.6% of the prognostic model content for estimat-
ing SCD, with the addition of SSS providing only a modestn
improvement in information content (20).ant role of peri-infarction myocardial ischemia in
ddition to the extent of myocardial infarction scar
or the prediction of risk for ventricular tachycardia
nd SCD. Myocardial perfusion imaging and echo-
ardiography are widely available and relatively
nexpensive for quantitative assessment of the ex-
ent of myocardial ischemia and scar. Cardiac mag-
etic resonance imaging and cardiac computed to-
ography also hold substantial potential for
ssessment of the extent of myocardial ischemia and
car, but further study is needed to establish the
elative value of these newer and more costly resources.
ympathetic Innervation
lthough coronary, myocardial, and valvular heart
isease usually provide the structural substrate,
ympathetic nervous system activation is often the
rigger for life-threatening ventricular arrhythmias.
mpaired global LV sympathetic innervation and
egional myocardial sympathetic heterogeneity are
rrhythmogenic (22) and can be imaged with planar
Fig. 5) (23) and/or SPECT imaging with meta-
odobenzylguanidine (mIBG) labeled with radioac-
ive iodine (123I) (24) or by positron emission
omography (PET) with tracers including hy-
roxyephedrine labeled with radioactive carbon
11C) (25). The importance of adrenergic stimula-
ion in the outcome of patients with heart failure is
upported by prediction based on plasma norepi-
ephrine levels (26) and measures of spillover of
No Ischemia
ears
2 3 4
verter-Deﬁbrillator Therapy by Myocardial Ischemia
appropriate implantable cardiac deﬁbrillator therapy in patients
ratiﬁed by the presence or absence of myocardial ischemia
in the Cox multivariate model were a history of spontaneous sus-
terval [CI]: 1.3. to 3.8; p  0.01), inducible ventricular tachycardia
myocardial ischemia (HR: 2.1; 95% CI: 1.2 to 3.5; p  0.01). Repro-Y
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105irculation (27). Beta-2 adrenergic receptor stimu-
ation can initiate ventricular tachycardia by non–
e-entrant mechanisms in the setting of heart fail-
re (28). Indirect evidence for the importance of the
ympathetic nervous system in arrhythmogenesis
omes from the effectiveness of beta-adrenergic
locking drugs in the prevention of life-threatening
ardiac arrhythmias and SCD (29).
Sympathetic nervous system imaging with
123I]mIBG has been shown to be an effective
redictor of mortality, and specifically of SCD, in
atients with heart failure. In a study of 112
atients with nonischemic dilated cardiomyopathy,
YHA functional class II to IV heart failure and
VEF 40%, Merlet et al. (30) found the heart to
ediastinum (H/M) ratio of [123I]mIBG and the
VEF to be the only independent predictors of
ortality over 27  20 months of follow-up.
ortality was not predicted by the maximum con-
umption of oxygen during exercise, invasive mea-
ures of right heart pressure, plasma norepineph-
ine, or LV diastolic dimension. Importantly, the
/M ratio of [123I]mIBG at 4 h after tracer
njection was the only independent predictor of
CD. Numerous small studies have confirmed the
apability of [123I]mIBG imaging to identify pa-
ients at increased risk for spontaneous ventricular
achycardia (31–34), ventricular fibrillation (34,35),
ppropriate discharge of an ICD (36,37), and SCD
38,39). Preliminary results have been reported
rom paired phase III clinical trials including 964
atients with heart failure and 110 control subjects
maged with [123I]mIBG and followed for 2 years
Figure 5. H/M Ratio of Sympathetic Nerve Activity From [123I]m
Example of the heart to mediastinum (H/M) ratio calculated from a
a patient with severe heart failure (H/M ratio 1.02). (B) Image from
with permission from Gerson et al. (23).or end points of cardiac death, heart failure pro- dression, sustained ventricular arrhythmia, aborted
ardiac arrest, or ICD discharge (40). Patients with
n H/M ratio 1.20 had a 10-fold increase in
ajor cardiac events compared with patients with
n H/M ratio 1.60. When the analysis was
estricted to patients with LVEF 30%, an H/M
atio1.6 remained a significant predictor of major
ardiac events compared with patients with an H/M
atio 1.60. Approximately 40% of study patients
ad an ICD during follow-up facilitating detection
f arrhythmic events. An H/M ratio 1.6 was a
ignificant predictor of major arrhythmic events.
linical Implications
he ICD is an effective but costly tool for prevention
f SCD. Currently, therapies that cost $50,000 per
ear of life saved are considered to be an appropriate
se of medical financial resources. Selection of patients
or ICD placement based on LVEF alone appears to
elect some subgroups in which the ICD is cost
ffective and other subgroups in whom it is not (e.g.,
atients who die from progressive heart failure or in
hom no life-threatening arrhythmia occurs). Cardiac
ympathetic imaging has demonstrated an indepen-
ent ability to predict life-threatening arrhythmias,
eyond prediction by LVEF alone. Impaired global
nd regional sympathetic nerve function images can
easonably be expected to improve the positive predic-
ive value for identification of patients at highest risk
or SCD. Cardiac imaging of myocardial scar, ische-
ia, and innervation all show substantial promise for
mprovement in accuracy of prediction of arrhythmic
iodobenzylguanidine
I]meta-iodobenzylguanidine planar anterior image. (A) Image from
tient with moderate heart failure (H/M ratio 1.55). Reproducedeta-
[123
a paeath compared with the use of LVEF alone.
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106uture Directions
uture patient selection for ICD placement may rely
n the use of combinations of imaging modalities that
ay complement or replace primary reliance on
VEF. One of the more promising approaches is the
ssessment of imbalance of myocardial perfusion and
nnervation. The presence of an innervation/perfusion
ismatch, in which a peri-infarction zone of sympa-
hetic denervation extends beyond the area of myo-
ardial scar, provides a potential substrate for re-
ntrant or triggered ventricular arrhythmias and
rrhythmic death (9,22,41,42). Hayashi et al. (43)
ollowed 40 patients with prior myocardial infarction,
ustained ventricular arrhythmia, and ICD placement
or 2 years with serial noninvasive electrophysiologic
tudies. In their study, the extent of innervation/
erfusion mismatch was related to long-term variabil-
ty in induced arrhythmias and was predictive of the
mergence of spontaneous ventricular tachycardia or
brillation. In addition to the presence and extent of
yocardial scar, demonstration by perfusion imaging
f the presence of viable myocardium, with reduced
lood flow and chronic regional dysfunction (i.e.,
ibernating myocardium), has been shown to identify
n important substrate for ventricular tachycardia and
brillation (12). In a chronic porcine model of left
nterior descending coronary artery occlusion, Sasano
t al. (25) found regionally impaired catecholamine
Figure 6. Perfusion/Innervation Mismatch and VT Site of Origin
Correlation of perfusion/innervation mismatch location and site of e
VT. (Left, top) Positron emission tomography polarmaps show regio
innervation by 11C-epinephrine retention. (Left, bottom) Extent ma
of denervation exceeds the region of hypoperfusion, producing a m
depicted in an anterior projection, show reduced bipolar endocardi
show the earliest activation of VT in the infarct border zone in the
Sasano et al. (25). LV  left ventricular; RV  right ventricle.ptake and storage using PET imaging in the nor-
ally perfused border zone around the infarct (Fig. 6).
he border zone containing an innervation/perfusion
ismatch was the site of earliest activation of ventric-
lar tachycardia on electrophysiologic testing (Fig. 7).
educed survival in a context of hibernating myocar-
ium and reduced LV function (44) is likely related, at
east in part, to arrhythmic death (45). An ongoing
ulticenter study (PAREPET [Prediction of Ar-
hythmic Events with Positron Emission Tomogra-
hy]) uses PET imaging of myocardial perfusion with
mmonia labeled with radioactive nitrogen (13N) and
ympathetic innervation with 11C-hydroxyephedrine
o assess risk for SCD in patients with ischemic
ardiomyopathy and LVEF 35%. The study is
esigned to assess the contributions of hibernating
yocardium and myocardial denervation to the
enesis of SCD in patients with ischemic cardio-
yopathy (46).
Imaging assessment of regional inhomogeneity of
drenergic innervation also holds promise for identi-
ying patients with heart failure at risk for SCD. In
atients with ventricular tachycardia, in the absence of
nderlying coronary artery disease, regional sympa-
hetic denervation detected by [123I]mIBG imaging
as been reported, whereas it was absent in
atients without ventricular tachycardia (47). In a
tudy of 11 patients with sustained ventricular
est activation of ventricular tachycardia (VT) in an animal model of
distribution of perfusion with 13N-ammonia and of sympathetic
f reduced perfusion and innervation. (Right, bottom) The extent
atch. (Right, top) Three-dimensional electroanatomic maps,
ltage in the apex and distal anteroseptal wall. Propagation maps
l anterior wall (red arrow). Reproduced with permission fromarli
nal
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107achycardia or SCD, Calkins et al. (48) per-
ormed 11C-hydroxyephedrine imaging followed
y electrophysiologic mapping at the time of defibril-
ator implantation. The effective refractory period in
yocardial regions with reduced 11C-hydroxyephedrine
etention was prolonged significantly compared with
egions with normal tracer retention. These findings
rovide a correlation of scintigraphic evidence of
egional sympathetic neuronal dysfunction and abnor-
al ventricular refractoriness in the human heart,
hereby predisposing to re-entrant arrhythmias. Cli-
icians imaging regional sympathetic innervations
ust take into account the baseline heterogeneity of
ympathetic nerve distribution in normal individuals
nd must also overcome the technical challenges of
ccurately quantitating regional sympathetic activity in
context of reduced global sympathetic innervation
esulting from heart failure. In this regard, the superior
patial resolution of PET imaging may prove advan-
ageous relative to [123I]mIBG SPECT imaging.
Improved prediction of life-threatening ventricular
rrhythmias may be facilitated by combining predic-
ive data from imaging studies with nonimaging tests
ssociated with electrical instability or with assays of
eurohumoral substances. For example, reduced heart
ate variability, a marker of impaired cardiac sympa-
hetic nerve function, is associated with an increased
isk of SCD following myocardial infarction. Al-
hough results from small initial studies were variable
36,49,50), recently Tamaki et al. (51) evaluated 106
atients with chronic heart failure (LVEF 40%)
ith baseline [123I]mIBG imaging, signal-averaged
lectrocardiogram, time and frequency domain heart
%
 o
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Figure 7. Perfusion/Innervation Mismatch and Inducibility of VT
In experimental animals with a mid-left anterior descending artery
defect size was not signiﬁcantly different in animals inducible for ve
inducible. Animals that were inducible for VT had more extensive p
not inducible for VT (p  0.019). Reproduced with permission fromate variability parameters, and measurement of QT [nterval dispersion. After 65  31 months of follow-
p, 18 of 106 patients had died suddenly. By multi-
ariate Cox analysis, LVEF by radionuclide blood
ool scan and [123I]mIBG washout rate 27% were
ndependently associated with SCD (Fig. 8), whereas
ata from signal-averaged electrocardiogram, heart
ate variability, and QT dispersion were not predictive.
f note, abnormal washout of [123I]mIBG was inde-
endently predictive of SCD, not only in patients with
VEF 35% but also in patients with LVEF 35%
Fig. 9). Others have observed that patients with low
eart rate variability 3 months following myocardial
nfarction have an increased extent of innervation/
erfusion mismatch (52), but prognostic studies combin-
ng heart rate variability and innervation/perfusion mis-
atch are not yet available. Other noninvasive
lectrophysiologic approaches for identification of pa-
ients likely to benefit from ICD placement have pro-
uced variable results, including microvolt T-wave alter-
ans assessment. None of these approaches has been
dequately assessed in conjunction with imaging assess-
ent of myocardial scar, ischemia, and innervation.
Cardiac sympathetic nerve imaging has also been
ompared with or combined with data from plasma
eurohormone levels in an attempt to improve pre-
iction of major arrhythmic events. In a study of 337
atients with heart failure and LVEF 35%, B-type
atriuretic peptide (BNP) has been shown to be an
ndependent predictor of SCD (53). Nagahara et al.
37) used a combination of [123I]mIBG and plasma
NP concentration in 54 patients to predict lethal
ardiac arrhythmias resulting in appropriate ICD dis-
harge or SCD. By multivariate analysis, only the
rvation
efect
Perfusion/
Innervation
Mismatch
*p=0.02
Inducible VT (n=7)
No VT (n=4)
usion, positron emission tomography perfusion and innervation
cular tachycardia (VT) compared with animals that were not
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ano et al. (25).nne
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